Shots:
- Intas Pharmaceuticals, through its Accord subsidiaries, has completed the acquisition of Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta
- With the acquisition, Accord BioPharma, Intas’ U.S. specialty arm, continues Udenyca commercialization, offering patient-friendly administration options autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)
- Udenyca is a leukocyte growth factor used to reduce infection risk in patients with non-myeloid cancers undergoing myelosuppressive chemotherapy and to improve survival after acute radiation exposure (Hematopoietic Subsyndrome of ARS)
Ref: PRNewsWire | Image: Intas & Coherus | Press Release
Related News:- Intas Pharmaceuticals Acquires Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
